Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.42 |
| ▸ | TYK2 | P29597 | 4/20 | 0.42 |
| ▸ | JAK3 | P52333 | 4/20 | 0.42 |
| ▸ | JAK1 | P23458 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.37 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17258976 | 0.93 | TP53 (0.42) | JAK2TYK2JAK3TP53KCNA5 | |
| SCHEMBL21048808 | 0.89 | TP53 (0.44) | JAK2TYK2JAK3JAK1TP53 | |
| SCHEMBL28840926 | 0.83 | TP53 (0.48) | JAK2TYK2JAK3JAK1TP53 | |
| SCHEMBL12280397 | 0.81 | KMT2A (0.47) | TP53KCNA5KDM4ACA12CA1 | |
| SCHEMBL21048878 | 0.78 | JAK2 (0.44) | JAK2TYK2JAK3JAK1TP53 | |
| SCHEMBL24352770 | 0.77 | KCNA5 (0.49) | KCNA5KDM4ACA12CA1CA7 | |
| SCHEMBL28831016 | 0.77 | KCNA5 (0.49) | KCNA5KDM4ACA12CA1CA7 | |
| SCHEMBL17258939 | 0.76 | TP53 (0.50) | JAK2TYK2JAK3JAK1TP53 | |
| SCHEMBL12663115 | 0.76 | KCNA5 (0.48) | KCNA5CTSKKDM4ANQO2 | |
| SCHEMBL8018113 | 0.75 | KCNA5 (0.56) | KCNA5CTSKKDM4ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143021-B1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10022376-B2 | Pyrazolopyridines and pyrazolopyrimidines | PFIZER INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3143021-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | Pfizer Inc (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20170071946-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-9518052-B2 | Pyrazolopyridines and pyrazolopyrimidines | PFIZER INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150329542-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. | 2015-11-19 | — | — | US | disclosed |
| WO-2015173683-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10022376-B2 | Pyrazolopyridines and pyrazolopyrimidines | CBR3, HRH4, REN | JAK2 78/4885TYK2 858/4885JAK3 392/4885 |
| US-20150329542-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | HRH2, HRH4, HRH1 | JAK2 501/4885TYK2 1438/4885JAK3 1185/4885 |
| US-20170071946-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | HRH2, HRH4, HRH1 | JAK2 501/4885TYK2 1438/4885JAK3 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.